Rakuten Securities Inc. Sells 13,541 Shares of Tempus AI, Inc. $TEM

Rakuten Securities Inc. trimmed its position in shares of Tempus AI, Inc. (NASDAQ:TEM) by 59.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,252 shares of the company’s stock after selling 13,541 shares during the quarter. Rakuten Securities Inc.’s holdings in Tempus AI were worth $546,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI in the third quarter valued at $26,000. GAMMA Investing LLC bought a new stake in shares of Tempus AI in the 3rd quarter worth about $28,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Tempus AI during the 3rd quarter worth about $38,000. Tsfg LLC grew its holdings in Tempus AI by 1,515.2% during the 3rd quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after purchasing an additional 500 shares during the last quarter. Finally, Cloud Capital Management LLC bought a new position in Tempus AI during the 3rd quarter valued at about $44,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Trading Down 7.3%

TEM stock opened at $51.44 on Friday. Tempus AI, Inc. has a 12 month low of $41.73 and a 12 month high of $104.32. The firm’s 50-day moving average is $50.87 and its 200 day moving average is $65.13. The company has a market capitalization of $9.20 billion, a PE ratio of -36.48 and a beta of 4.90. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Wednesday, March 11th. TD Cowen raised Tempus AI from a “hold” rating to a “buy” rating and set a $65.00 target price on the stock in a research note on Monday, April 13th. HC Wainwright increased their price target on Tempus AI from $89.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Robert W. Baird started coverage on Tempus AI in a research note on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price target for the company. Finally, JPMorgan Chase & Co. dropped their price objective on Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and an average price target of $71.36.

Insiders Place Their Bets

In other news, EVP Andrew Polovin sold 10,949 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19. Following the transaction, the executive vice president directly owned 126,918 shares of the company’s stock, valued at approximately $7,654,424.58. This trade represents a 7.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Erik Phelps sold 9,464 shares of Tempus AI stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.43, for a total transaction of $562,445.52. Following the sale, the executive vice president directly owned 79,816 shares of the company’s stock, valued at $4,743,464.88. This represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 563,841 shares of company stock worth $32,258,311. 24.26% of the stock is owned by company insiders.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.